Clinical features of 5 tFL-PMBLsig-pos cases
| . | 1 . | 2 . | 3 . | 4 . | 5 . |
|---|---|---|---|---|---|
| EX00406 . | EX00408 . | EX004010 . | FL1179T2 . | FL1122T2 . | |
| Age (y) | 61 | 72 | 62 | 74 | 51 |
| Gender | M | F | M | M | M |
| FL histologic grade | 3A and 1-2 | 3A | 1-2 | 1 | 1 |
| Time from FL to tFL-PMBLsig-pos (y) | 7 | 12 | 0 | 6 | 1 |
| Prior treatment | R-CHOP, venetoclax, R-ICE, BR, R-GemOx, axicabtagene ciloleucel | R-CHOP, R-ESHAP, R-ICE, lenalidomide | None | R-CVP | Chlorambucil, ACOP-12 |
| Biopsy site | Paraspinal LN | Inguinal LN | Thyroid | Axillary LN | Liver |
| Mediastinal disease | No | No | No | No | No |
| Ann Arbor stage | III | I | III | NA | NA |
| Treatment of tFL-PMBLsig-pos | R2, Pola-R, RT | Rituximab, BR | R-CHOP | R-CHOP, RT | RT, cyclophosphamide |
| Outcome | DWD | AWD | DNED | ANED | DWD |
| Follow-up time from tFL-PMBLsig-pos diagnosis (y) | 0.7 | 2.9 | 1.7 | 10.8 | 0.7 |
| . | 1 . | 2 . | 3 . | 4 . | 5 . |
|---|---|---|---|---|---|
| EX00406 . | EX00408 . | EX004010 . | FL1179T2 . | FL1122T2 . | |
| Age (y) | 61 | 72 | 62 | 74 | 51 |
| Gender | M | F | M | M | M |
| FL histologic grade | 3A and 1-2 | 3A | 1-2 | 1 | 1 |
| Time from FL to tFL-PMBLsig-pos (y) | 7 | 12 | 0 | 6 | 1 |
| Prior treatment | R-CHOP, venetoclax, R-ICE, BR, R-GemOx, axicabtagene ciloleucel | R-CHOP, R-ESHAP, R-ICE, lenalidomide | None | R-CVP | Chlorambucil, ACOP-12 |
| Biopsy site | Paraspinal LN | Inguinal LN | Thyroid | Axillary LN | Liver |
| Mediastinal disease | No | No | No | No | No |
| Ann Arbor stage | III | I | III | NA | NA |
| Treatment of tFL-PMBLsig-pos | R2, Pola-R, RT | Rituximab, BR | R-CHOP | R-CHOP, RT | RT, cyclophosphamide |
| Outcome | DWD | AWD | DNED | ANED | DWD |
| Follow-up time from tFL-PMBLsig-pos diagnosis (y) | 0.7 | 2.9 | 1.7 | 10.8 | 0.7 |
ACOP-12, doxorubicin, cyclophosphamide, vincristine; AWD, alive with disease; BR, bendamustine and rituximab; DNED, died with no evidence of disease; DWD, died with disease; F, female; LN, lymph node; M, male; NA, not available; Pola-R, polatuzumab vedotin and rituximab; R2, lenalidomide and rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, prednisone; R-ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, and cisplatin; R-GemOx, rituximab, gemcitabine, and oxaliplatin; R-ICE, rituximab, ifosfamide, carboplatin, and etoposide; RT, radiation therapy.